Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

In early November, Viracta said it would be waving goodbye to 42% of its remaining staff in order to keep money flowing to its lead program, a combination of the HDAC inhibitor nanatinostat and ...

The Company’s oncology aPKCi inhibitor is a novel, first in class drug candidateWARRINGTON, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: ...

The claims also include combination therapies comprising use of the hedgehog pathway inhibitors along with an HDAC inhibitors enhancing anti-cancer efficacy. "Issuance of the new patent for our ...

CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity in 2024 after licensing ivaltinostat from CG ...

Short-chain fatty acids (SCFAs) like propionate and butyrate are critical byproducts of dietary fiber digestion. These ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the issuance of a new patent in Japan for its ...

Biodexa Strengthens Management TeamAppointment of Dr Gary A. Shangold as Chief Medical OfficerBiodexa Pharmaceuticals PLC ...

Melanoma is responsible for about 80% of skin cancer deaths worldwide, particularly in cases with metastasis. Melanoma shows resistance to standard therapy and the search for novel treatment options ...

HDAC inhibitors and chemotherapy. Ultimately, the aim is to extend the time to relapse and prevent tumour resistance developing, in the hopes of effecting a functional cure for the cancer in more ...

Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical ...